Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 1/20 | 0.49 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.46 |
| ▸ | BRD4 | O60885 | 3/20 | 0.40 |
| ▸ | FYN | P06241 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 2/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.39 |
| ▸ | WEE1 | P30291 | 3/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29448998 | 1.00 | ULK1 (0.49) | ULK1ULK2MAPK9MAPK10BRD4 | |
| SCHEMBL29449166 | 0.98 | ULK1 (0.49) | ULK1ULK2MAPK9MAPK10BRD4 | |
| SCHEMBL22634498 | 0.98 | ULK1 (0.49) | ULK1ULK2MAPK9MAPK10BRD4 | |
| SCHEMBL22634739 | 0.89 | ULK1 (0.47) | ULK1ULK2MAPK9MAPK10EGFR | |
| SCHEMBL29449038 | 0.89 | ULK1 (0.47) | ULK1ULK2MAPK9MAPK10EGFR | |
| SCHEMBL22634554 | 0.89 | ULK1 (0.53) | ULK1ULK2MAPK9MAPK10BRD4 | |
| SCHEMBL29448982 | 0.89 | ULK1 (0.53) | ULK1ULK2MAPK9MAPK10BRD4 | |
| SCHEMBL22652083 | 0.88 | ULK1 (0.48) | ULK1ULK2MAPK9MAPK10BRD4 | |
| SCHEMBL22634453 | 0.88 | MAPK9 (0.39) | ULK1ULK2MAPK9MAPK10PTK2 | |
| SCHEMBL29449006 | 0.88 | MAPK9 (0.39) | ULK1ULK2MAPK9MAPK10PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12071432-B2 | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-08-27 | — | — | US | claimed |
| CN-114127057-B | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof | 德西费拉制药有限责任公司 | 2024-07-12 | — | — | CN | claimed |
| EP-4342469-A2 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2024-03-27 | — | — | EP | claimed |
| EP-3966207-B1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS LLC (US) | 2023-11-01 | — | — | EP | claimed |
| US-20230039712-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-02-09 | — | — | US | claimed |
| US-11530206-B2 | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-12-20 | — | — | US | claimed |
| EP-3966207-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2022-03-16 | — | — | EP | claimed |
| CN-114127057-A | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof | 德西费拉制药有限责任公司 | 2022-03-01 | — | — | CN | claimed |
| WO-2020231806-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2020-11-19 | — | — | WO | claimed |
| US-20200354352-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2020-11-12 | — | — | US | claimed |
| US-20250084073-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2025-03-13 | — | — | US | disclosed |
| US-12071432-B2 | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-08-27 | — | — | US | disclosed |
| CN-114127057-B | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof | 德西费拉制药有限责任公司 | 2024-07-12 | — | — | CN | disclosed |
| EP-4342469-A2 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2024-03-27 | — | — | EP | disclosed |
| EP-3966207-B1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS LLC (US) | 2023-11-01 | — | — | EP | disclosed |
| US-11530206-B2 | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-12-20 | — | — | US | disclosed |
| EP-3966207-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| CN-114127057-A | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof | 德西费拉制药有限责任公司 | 2022-03-01 | — | — | CN | disclosed |
| WO-2020231806-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2020-11-19 | — | — | WO | disclosed |
| US-20200354352-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2020-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039712-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | BECN1, SQSTM1, ATG7 | ULK1 4/4885ULK2 9/4885MAPK9 2169/4885 |
| US-11530206-B2 | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof | BECN1, SQSTM1, ATG7 | ULK1 4/4885ULK2 9/4885MAPK9 2169/4885 |
| US-12071432-B2 | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof | BECN1, SQSTM1, ATG7 | ULK1 4/4885ULK2 9/4885MAPK9 2169/4885 |
| US-20200354352-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | BECN1, SQSTM1, ATG7 | ULK1 4/4885ULK2 9/4885MAPK9 2169/4885 |
| US-20250084073-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | BECN1, SQSTM1, ATG7 | ULK1 4/4885ULK2 9/4885MAPK9 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.